 Connection
Michael Birrer to Uterine Cervical Neoplasms
This is a "connection" page, showing publications Michael Birrer has written about Uterine Cervical Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.256 |
|
|
|
-
Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1204-1211.
Score: 0.781
-
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
Score: 0.591
-
Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 02; 21(1):106.
Score: 0.152
-
Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande SA, Lin YG, Schilder RJ, Birrer MJ, Kast WM. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 11 01; 26(21):5621-5630.
Score: 0.148
-
Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 1999 Oct 15; 59(20):5270-4.
Score: 0.139
-
Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 1997 Jun 01; 57(11):2112-5.
Score: 0.118
-
Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR, Birrer MJ. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb; 64(2):242-51.
Score: 0.115
-
Maritz MF, van der Watt PJ, Holderness N, Birrer MJ, Leaner VD. Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression. Biol Chem. 2011 May; 392(5):439-48.
Score: 0.077
-
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8.
Score: 0.076
-
Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1). Gynecol Oncol. 2000 Aug; 78(2):113-22.
Score: 0.037
-
Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol. 2004 Feb; 92(2):596-602.
Score: 0.012
-
Geradts J, Maynard R, Birrer MJ, Hendricks D, Abbondanzo SL, Fong KM, Barrett JC, Lombardi DP. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Am J Pathol. 1999 Jun; 154(6):1665-71.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|